Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11371860 | PMC |
| http://dx.doi.org/10.1007/s00401-024-02792-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unraveling the Molecular Basis of Extracranial Glioblastoma Metastasis: A Case Report and Literature Review.
Neuropathology
October 2025
Pathology Department, Complejo Hospitalario Universitario de Toledo, Toledo, Spain.
Glioblastoma (GB), IDH-wildtype (IDH-wt), is the most prevalent primary malignant brain neoplasm in adults. Despite adjuvant therapy, the prognosis for these tumors remains dismal, with a median survival of around 15-18 months. Although rare, extracranial metastases from GB are reported with increasing frequency, likely due to advancements in follow-up, treatments, and improved patient survival.
View Article and Find Full Text PDFComparative Analysis of MRI Features and Overall Survival: IDH-Wildtype Diffuse Lower-grade Glioma and Glioblastoma in Adults.
Acad Radiol
September 2025
Department of Radiology, The First Medical Center of Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, China (X.Y., X.M., J.Z., Y.Z., G.L., F.X., C.H., X.L.). Electronic address:
Rationale And Objectives: In depth comparison of imaging features and overall survival (OS) between IDH wild-type diffuse lower-grade glioma and glioblastoma (GB), providing precise guidance for early risk stratification and optimized clinical decision-making.
Materials And Methods: Retrospective inclusion of IDH wild-type glioma patients admitted between January 2017 and January 2024. Patients were classified into GB (histological and molecular) and lower-grade glioma not elsewhere classified (LGNEC) based on fifth edition of the Central Nervous System Tumor Classification Standards.
cIMPACT-NOW update 11: Proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumors.
Brain Pathol
August 2025
Department of Pathology, Massachusetts General Hospital, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
The Consortium to Inform Molecular and Practical Approaches to Central Nervous System Tumor Taxonomy (cIMPACT-NOW) updates provide guidelines for the diagnosis of central nervous system (CNS) tumors and suggestions for future World Health Organization (WHO) classification. Following publication of the fifth edition WHO Classification of CNS Tumors (WHO CNS5) in 2021, the cIMPACT-NOW working group "Clarification" reviewed WHO CNS5 and prioritized two topics for further elucidation: (a) distinction of Glioblastoma, IDH-wildtype from Diffuse pediatric-type high-grade glioma, H3-wildtype, and IDH-wildtype and (b) clarification of subgroups of posterior fossa (PF) ependymal tumors. Recommendations regarding the IDH- and H3-wildtype diffuse high-grade gliomas include: (1) use caution assigning CNS WHO grade 4 (diagnosis of Glioblastoma, IDH-wildtype) to a "TERT promoter only", histologically low-grade, IDH-wildtype tumor; (2) EGFR gene amplification and +7/-10 chromosome copy number alterations should not be used as solitary defining features for diagnosing high-grade gliomas as Glioblastoma, IDH-wildtype in patients <40 years of age; (3) Diffuse pediatric-type high-grade glioma, H3-wildtype, and IDH-wildtype should be considered in the differential diagnosis in adults, especially those <40 years of age; (4) PDGFRA alteration, EGFR alteration, or MYCN amplification count as key molecular features of Diffuse pediatric-type high-grade glioma, H3-wildtype, and IDH-wildtype only in patients <25 years.
View Article and Find Full Text PDFIoning out glioblastoma: ferroptosis mechanisms and therapeutic frontiers.
Cell Death Discov
August 2025
Clinical Laboratory and Qingdao Key Laboratory of Immunodiagnosis, Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital), Qingdao, China.
Glioblastoma (GBM) (IDH-wildtype), the most prevalent and malignant primary brain tumor in adults, continues to pose a major therapeutic challenge in neuro-oncology. Despite significant advancements in cancer diagnosis and treatment technologies, conventional therapies remain largely ineffective against this tumor, urgently necessitating breakthrough treatment strategies. This comprehensive review critically examines recent advances in targeting ferroptosis, an iron-dependent form of non-apoptotic cell death mediated through reactive oxygen species (ROS) accumulation and lipid membrane peroxidation, for therapeutic intervention in GBM.
View Article and Find Full Text PDFHydroxytyrosol and Brain Tumors: Mechanisms of Action and Therapeutic Potential.
Curr Issues Mol Biol
August 2025
Experimental and Clinical Physiopathology Research Group CTS-1039, Department of Health Sciences, School of Health Sciences, University of Jaén, E-23071 Jaén, Spain.
Central nervous system (CNS) tumors, especially gliomas and IDH-wildtype glioblastoma, present high aggressiveness, low response to current treatments and limited survival. Several biological processes such as oxidative stress, inflammation, apoptosis, and autophagy are involved in their development. Hydroxytyrosol (HTX), a phenolic compound present in olives, has shown relevant effects on these processes in experimental models.
View Article and Find Full Text PDF